LFCR
Lifecore Biomedical, Inc.
There isn't enough reported data to score LFCR yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LFCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Stable | |
| Weak |
LFCR's cash flow is currently stable, but its profitability and balance sheet are weak. There isn't enough data to rate its revenue.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LFCR PE Valuation
LFCR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LFCR Forward outlook
There aren't enough analyst estimates for LFCR to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LFCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.16 | +$0.11 |
| Q2 2025 | -$1.27 | -497% |
| Q1 2025 | -$1.39 | -$0.53 |
| Q4 2024 | -$0.50 | +$2.11 |
| Q3 2024 | $0.14 | +$3.56 |
| Q2 2024 | $0.32 | +$3.77 |
| Q1 2024 | -$0.86 | +$3.11 |
| Q4 2023 | -$2.61 | +$0.46 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 490% for LFCR versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
LFCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.3M | -19% |
| Q2 2026 | $34.2M | -6.2% |
| Q1 2026 | $23.2M | -34% |
| Q4 2025 | $44.4M | +36% |
| Q3 2025 | $31.1M | +26% |
| Q2 2025 | $36.4M | -3.8% |
| Q1 2025 | $35.2M | -1.5% |
| Q4 2024 | $32.6M | +8% |
LFCR's revenue has slid since its 2020 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.5% | +6.3 points |
| Q2 2026 | 7.5% | -7.1 points |
| Q1 2026 | -20% | +5.5 points |
| Q3 2025 | -9.9% | +37 points |
| Q2 2025 | 15% | +8.9 points |
| Q1 2025 | -26% | -23 points |
| Q4 2024 | -6% | -1.1 points |
| Q3 2024 | -47% | -12 points |
LFCR's operating margin was −3.5% last quarter, down 18 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LFCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LFCR on profitability, with a higher operating margin.
LFCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6M | +24036% |
| Q2 2026 | -$2.7M | -183% |
| Q1 2026 | $3.6M | +$7.8M |
| Q4 2025 | -$986.3K | +$7.6M |
| Q3 2025 | $25K | +$4.1M |
| Q2 2025 | $3.3M | -62% |
| Q1 2025 | -$4.3M | +$3.5M |
| Q4 2024 | -$8.6M | -$5.6M |
LFCR's free cash flow has turned positive after six years mostly in the red: $6M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LFCR on cash flow, with more consistent year-over-year improvement.
LFCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +271K shares |
| 1 year | +1.2% | +443K shares |
| 3 years | +24% | +7.4M shares |
| 5 years | +29% | +8.4M shares |
| Available history | +30% | +8.7M shares |
LFCR has 38M diluted shares, up 1.2% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LFCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LFCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | 5,820.6x | High |
| Q3 2021 | 8.2x | High |
| Q2 2021 | 25.7x | High |
| Q4 2019 | 8.5x | High |
LFCR's net debt is more than 20 years of its operating earnings (EBITDA).
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LFCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 90.1 | Overbought |
LFCR's weekly RSI is 61 (neutral) and its Stochastic is 90 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LFCR PE vs Healthcare Sector
| Metric | LFCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFCR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LFCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.14 | 4.2% above |
| 20 week MA | $5.21 | 23% above |
| 50 week MA | $5.85 | 9.4% above |
| 100 week MA | $6.38 | 0.3% above |
| 200 week MA | $6.45 | 0.8% below |
LFCR has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 0.8% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LFCR on trend strength, trading above more of its moving averages.
LFCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $10.1 | -12% |
| 2021 | $10.1 | $11.0 | +8.7% |
| 2022 | $11.0 | $6.93 | -37% |
| 2023 | $6.93 | $6.19 | -11% |
| 2024 | $6.19 | $7.28 | +18% |
| 2025 | $7.28 | $8.30 | +14% |
| 2026 YTD | $8.30 | $6.40 | -23% |
LFCR has finished lower in three of the last six years. It's down 23% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LFCR on returns for 2026, with the stronger performance.